Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

51 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia.
Kudlacz E, Conklyn M, Andresen C, Whitney-Pickett C, Changelian P. Kudlacz E, et al. Eur J Pharmacol. 2008 Mar 17;582(1-3):154-61. doi: 10.1016/j.ejphar.2007.12.024. Epub 2007 Dec 28. Eur J Pharmacol. 2008. PMID: 18242596
Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule alpha4beta1 antagonists.
Kudlacz E, Whitney C, Andresen C, Duplantier A, Beckius G, Chupak L, Klein A, Kraus K, Milici A. Kudlacz E, et al. J Pharmacol Exp Ther. 2002 May;301(2):747-52. doi: 10.1124/jpet.301.2.747. J Pharmacol Exp Ther. 2002. PMID: 11961081
Isoxazolyl, oxazolyl, and thiazolylpropionic acid derivatives as potent alpha(4)beta(1) integrin antagonists.
Duplantier AJ, Beckius GE, Chambers RJ, Chupak LS, Jenkinson TH, Klein AS, Kraus KG, Kudlacz EM, McKechney MW, Pettersson MP, Whitney CA, Milici AJ. Duplantier AJ, et al. Among authors: kudlacz em. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2593-6. doi: 10.1016/s0960-894x(01)00511-x. Bioorg Med Chem Lett. 2001. PMID: 11551757
Characterization of chemokine CCR3 agonist-mediated eosinophil recruitment in the Brown-Norway rat.
Kudlacz EM, Whitney CA, Andresen CJ, Umland JP, Cheng JB. Kudlacz EM, et al. Br J Pharmacol. 1999 Oct;128(3):788-94. doi: 10.1038/sj.bjp.0702835. Br J Pharmacol. 1999. PMID: 10516663 Free PMC article.
Genetic ablation of the src kinase p59fynT exacerbates pulmonary inflammation in an allergic mouse model.
Kudlacz EM, Andresen CJ, Salafia M, Whitney CA, Naclerio B, Changelian PS. Kudlacz EM, et al. Am J Respir Cell Mol Biol. 2001 Apr;24(4):469-74. doi: 10.1165/ajrcmb.24.4.4266. Am J Respir Cell Mol Biol. 2001. PMID: 11306441
Combined tachykinin receptor antagonists for the treatment of respiratory diseases.
Kudlacz EM. Kudlacz EM. Expert Opin Investig Drugs. 1998 Jul;7(7):1055-62. doi: 10.1517/13543784.7.7.1055. Expert Opin Investig Drugs. 1998. PMID: 15992015
The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models.
Kudlacz E, Perry B, Sawyer P, Conklyn M, McCurdy S, Brissette W, Flanagan And M, Changelian P. Kudlacz E, et al. Am J Transplant. 2004 Jan;4(1):51-7. doi: 10.1046/j.1600-6143.2003.00281.x. Am J Transplant. 2004. PMID: 14678034
Functional effects of eotaxin are selectively upregulated on IL-5 transgenic mouse eosinophils.
Kudlacz E, Whitney C, Andresenl C, Conklyn M. Kudlacz E, et al. Inflammation. 2002 Jun;26(3):111-9. doi: 10.1023/a:1015548414274. Inflammation. 2002. PMID: 12083417
The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing.
Conklyn M, Andresen C, Changelian P, Kudlacz E. Conklyn M, et al. Among authors: kudlacz e. J Leukoc Biol. 2004 Dec;76(6):1248-55. doi: 10.1189/jlb.0504282. Epub 2004 Sep 15. J Leukoc Biol. 2004. PMID: 15371489
A supratherapeutic dose of the Janus kinase inhibitor tasocitinib (CP-690,550) does not prolong QTc interval in healthy participants.
Krishnaswami S, Kudlacz E, Wang R, Chan G. Krishnaswami S, et al. Among authors: kudlacz e. J Clin Pharmacol. 2011 Sep;51(9):1256-63. doi: 10.1177/0091270010379809. Epub 2010 Dec 8. J Clin Pharmacol. 2011. PMID: 21148043 Clinical Trial.
51 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page